You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

January 30, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA approves first generic version of Nexium

FDA approved the first generic version of Nexium to treat gastroesophageal reflux disease in adults and children aged 1 year and older. » Read more on one of the most frequently prescribed brand name drugs in the US

FDA approves remote continuous-glucose-monitoring app

The first set of mobile medical apps that will allow diabetic patients to share data with others from a continuous glucose monitor has received permission for marketing from FDA. » Why this technology will be valuable to caregivers of children with diabetes

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Pipeline agents for psoriatic arthritis and plaque psoriasisk

Psoriasis is a chronic, inflammatory disease that affects approximately 1% to 3% of the world population. Check out what’s in drug pipeline and read more on the approval of Otezla (apremilast). » Details

 

RELATED ARTICLES

[BLOG]: Cost containment through the use of generic medications

FDA approves combo pill for adults with type 2 diabetes

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group